Adial Pharmaceuticals, Inc. (ADIL)
NASDAQ: ADIL · Real-Time Price · USD
0.786
+0.017 (2.21%)
At close: Feb 21, 2025, 4:00 PM
0.762
-0.025 (-3.12%)
After-hours: Feb 21, 2025, 4:48 PM EST
Adial Pharmaceuticals Employees
As of December 31, 2023, Adial Pharmaceuticals had 7 total employees, including 4 full-time and 3 part-time employees. The number of employees decreased by 13 or -65.00% compared to the previous year.
Employees
7
Change (1Y)
-13
Growth (1Y)
-65.00%
Revenue / Employee
n/a
Profits / Employee
-$1,863,856
Market Cap
5.03M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
ADIL News
- 3 days ago - Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies - GlobeNewsWire
- 10 days ago - Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders - GlobeNewsWire
- 24 days ago - Adial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder - GlobeNewsWire
- 2 months ago - Adial Pharmaceuticals Granted Key U.S. Patent for the Treatment of Alcohol and Drug Dependence Based on Expanded Genotype Combinations - GlobeNewsWire
- 3 months ago - Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer - GlobeNewsWire
- 5 months ago - Adial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder - GlobeNewsWire
- 6 months ago - Adial Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 6 months ago - Adial Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire